156 related articles for article (PubMed ID: 22297723)
21. Tyk2 is dispensable for induction of myeloproliferative disease by mutant FLT3.
Nakajima H; Shibata F; Kumagai H; Shimoda K; Kitamura T
Int J Hematol; 2006 Jul; 84(1):54-9. PubMed ID: 16867903
[TBL] [Abstract][Full Text] [Related]
22. JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model.
Mercher T; Wernig G; Moore SA; Levine RL; Gu TL; Fröhling S; Cullen D; Polakiewicz RD; Bernard OA; Boggon TJ; Lee BH; Gilliland DG
Blood; 2006 Oct; 108(8):2770-9. PubMed ID: 16804112
[TBL] [Abstract][Full Text] [Related]
23. Role for the adaptor protein Grb10 in the activation of Akt.
Jahn T; Seipel P; Urschel S; Peschel C; Duyster J
Mol Cell Biol; 2002 Feb; 22(4):979-91. PubMed ID: 11809791
[TBL] [Abstract][Full Text] [Related]
24. The activation loop tyrosine 823 is essential for the transforming capacity of the c-Kit oncogenic mutant D816V.
Agarwal S; Kazi JU; Mohlin S; Påhlman S; Rönnstrand L
Oncogene; 2015 Aug; 34(35):4581-90. PubMed ID: 25435369
[TBL] [Abstract][Full Text] [Related]
25. Casitas B-lineage lymphoma mutants activate AKT to induce transformation in cooperation with class III receptor tyrosine kinases.
Polzer H; Janke H; Schmid D; Hiddemann W; Spiekermann K
Exp Hematol; 2013 Mar; 41(3):271-80.e4. PubMed ID: 23127761
[TBL] [Abstract][Full Text] [Related]
26. Tel/PDGFRbeta induces stem cell differentiation via the Ras/ERK and STAT5 signaling pathways.
Dobbin E; Graham C; Corrigan PM; Thomas KG; Freeburn RW; Wheadon H
Exp Hematol; 2009 Jan; 37(1):111-121. PubMed ID: 19100521
[TBL] [Abstract][Full Text] [Related]
27. 14-3-3 Integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1-transformed hematopoietic cells.
Dong S; Kang S; Gu TL; Kardar S; Fu H; Lonial S; Khoury HJ; Khuri F; Chen J
Blood; 2007 Jul; 110(1):360-9. PubMed ID: 17389761
[TBL] [Abstract][Full Text] [Related]
28. Bcr-Abl with an SH3 deletion retains the ability To induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy.
Gross AW; Zhang X; Ren R
Mol Cell Biol; 1999 Oct; 19(10):6918-28. PubMed ID: 10490629
[TBL] [Abstract][Full Text] [Related]
29. Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant.
Chian R; Young S; Danilkovitch-Miagkova A; Rönnstrand L; Leonard E; Ferrao P; Ashman L; Linnekin D
Blood; 2001 Sep; 98(5):1365-73. PubMed ID: 11520784
[TBL] [Abstract][Full Text] [Related]
30. Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformation.
Kamishimoto J; Tago K; Kasahara T; Funakoshi-Tago M
Cell Signal; 2011 May; 23(5):849-56. PubMed ID: 21255641
[TBL] [Abstract][Full Text] [Related]
31. c-Kit mutants require hypoxia-inducible factor 1alpha to transform melanocytes.
Monsel G; Ortonne N; Bagot M; Bensussan A; Dumaz N
Oncogene; 2010 Jan; 29(2):227-36. PubMed ID: 19802003
[TBL] [Abstract][Full Text] [Related]
32. c-kit Point mutation in patients with myeloproliferative disorders.
Kimura A; Nakata Y; Katoh O; Hyodo H
Leuk Lymphoma; 1997 Apr; 25(3-4):281-7. PubMed ID: 9168438
[TBL] [Abstract][Full Text] [Related]
33. Mastocytosis: a mutated KIT receptor induced myeloproliferative disorder.
Chatterjee A; Ghosh J; Kapur R
Oncotarget; 2015 Jul; 6(21):18250-64. PubMed ID: 26158763
[TBL] [Abstract][Full Text] [Related]
34. Gab2 is involved in differential phosphoinositide 3-kinase signaling by two splice forms of c-Kit.
Sun J; Pedersen M; Rönnstrand L
J Biol Chem; 2008 Oct; 283(41):27444-27451. PubMed ID: 18697750
[TBL] [Abstract][Full Text] [Related]
35. Ret oncogene signal transduction via a IRS-2/PI 3-kinase/PKB and a SHC/Grb-2 dependent pathway: possible implication for transforming activity in NIH3T3 cells.
Hennige AM; Lammers R; Arlt D; Höppner W; Strack V; Niederfellner G; Seif FJ; Häring HU; Kellerer M
Mol Cell Endocrinol; 2000 Sep; 167(1-2):69-76. PubMed ID: 11000521
[TBL] [Abstract][Full Text] [Related]
36. STAT5 requires the N-domain for suppression of miR15/16, induction of bcl-2, and survival signaling in myeloproliferative disease.
Li G; Miskimen KL; Wang Z; Xie XY; Brenzovich J; Ryan JJ; Tse W; Moriggl R; Bunting KD
Blood; 2010 Feb; 115(7):1416-24. PubMed ID: 20008792
[TBL] [Abstract][Full Text] [Related]
37. Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells.
Ning ZQ; Li J; Arceci RJ
Blood; 2001 Jun; 97(11):3559-67. PubMed ID: 11369651
[TBL] [Abstract][Full Text] [Related]
38. K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells.
Van Meter ME; Díaz-Flores E; Archard JA; Passegué E; Irish JM; Kotecha N; Nolan GP; Shannon K; Braun BS
Blood; 2007 May; 109(9):3945-52. PubMed ID: 17192389
[TBL] [Abstract][Full Text] [Related]
39. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes.
Wernig G; Gonneville JR; Crowley BJ; Rodrigues MS; Reddy MM; Hudon HE; Walz C; Reiter A; Podar K; Royer Y; Constantinescu SN; Tomasson MH; Griffin JD; Gilliland DG; Sattler M
Blood; 2008 Apr; 111(7):3751-9. PubMed ID: 18216297
[TBL] [Abstract][Full Text] [Related]
40. FOP-FGFR1 tyrosine kinase, the product of a t(6;8) translocation, induces a fatal myeloproliferative disease in mice.
Guasch G; Delaval B; Arnoulet C; Xie MJ; Xerri L; Sainty D; Birnbaum D; Pébusque MJ
Blood; 2004 Jan; 103(1):309-12. PubMed ID: 12969958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
